EDWARD ARIAS: Open Payments
NPI 1922018993 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,576 in 56 payments from 16 companies in 2025. Trend: 2023 $667 · 2024 $965 · 2025 $1,576
Food & beverage: $1,576
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $457 |
| UCB, Inc. | 19 | $299 |
| Vanda Pharmaceuticals Inc. | 6 | $138 |
| JAZZ PHARMACEUTICALS INC. | 1 | $122 |
| Lundbeck LLC | 4 | $112 |
| Exact Sciences Corporation | 4 | $107 |
| Amgen Inc. | 3 | $58 |
| Lilly USA, LLC | 3 | $50 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $47 |
| SK Life Science, Inc. | 1 | $35 |
Products named: Fintepla, REXULTI, HETLIOZ, EPIDIOLEX, INGREZZA, The Cologuard Plus Collection Kit, OTEZLA, MOUNJARO.
Industry payments across CA — which companies pay providers there.
